BLA Supports NovaSpira’s Bispecific Antibody NS-342 in Securing Phase I Clinical Trial Approval from South Korea’s MFDS
NovaSpira's bispecific antibody NS-342 received Phase I clinical trial approval from South Korea's M...
FDA Rare Disease Guidelines 2026 | Frank Li at KIC
Dr. Frank Li of BLA Regulatory will speak at 2026 KIC in Seoul on October 15, sharing recent FDA reg...
U.S. Regulatory Strategies for Biotech Companies 2026 | Online
Dr. Frank Li of BLA Regulatory will be a featured speaker at an online seminar hosted by R&D Support...
